Lisata Therapeutics, Inc. filings document material events, operating updates, and capital-structure matters for a clinical-stage pharmaceutical company focused on certepetide and related solid-tumor therapy development. Recent Form 8-K disclosures include financial results, Regulation FD materials, corporate presentations, material agreements, shareholder-voting matters, governance topics, and clinical or regulatory disclosures.
The filing record also documents changes to certepetide commercialization rights, including the termination of a Greater China license and collaboration agreement related to research, development, and commercialization of the product candidate. These disclosures frame Lisata’s formal reporting around program development, partnership economics, public-company governance, and transaction-related capital structure matters.
Lisata Therapeutics, Inc. reported equity awards and related tax withholdings for senior executive James Nisco, SVP Finance, Treasurer and Chief Accounting Officer. On January 9, 2026, he received 15,000 shares of restricted common stock at a price of $0 under the company’s 2018 Equity Incentive Compensation Plan. These restricted shares vest in four equal parts, with one quarter vesting on the grant date and additional quarters vesting on each of the first, second and third anniversaries of the grant.
The filing also shows tax-related share withholdings: blocks of 2,131, 2,131, 1,137 and 781 common shares were withheld at $1.97 per share to cover taxes upon vesting of restricted stock. After these transactions, Nisco directly held 32,311 shares of common stock, which include 20,750 unvested restricted shares.
In addition, Nisco was granted a stock option for 7,000 shares of common stock at an exercise price of $1.97 per share. One quarter of the option vested on the grant date, with further quarters scheduled to vest on the first, second and third anniversaries of January 9, 2026, and the option expires on January 9, 2036.
Lisata Therapeutics, Inc. executive Tariq Imam, SVP Business Development and General Counsel, reported new equity awards and related tax withholdings. On January 9, 2026, he received 15,000 shares of common stock as restricted stock awards under the company’s 2018 Equity Incentive Compensation Plan at a price of $0. These restricted shares vest in four equal parts: one-quarter on the grant date and one-quarter on each of the first three anniversaries.
After this grant, he directly owned 39,579 shares of common stock, including 17,750 unvested restricted shares. Several transactions coded "F" show a total of 1,401, 840, 747 and 513 shares of common stock withheld at $1.97 per share to cover tax liabilities from restricted stock vesting, leaving 36,078 common shares directly owned. Imam was also granted a stock option for 7,000 shares at an exercise price of $1.97 per share, with one-quarter vesting immediately on January 9, 2026 and the remainder vesting in three annual installments through an expiration date of January 9, 2036.
Lisata Therapeutics executive Kristen K. Buck, EVP, R&D and CMO, reported new equity awards and related tax-withholding transactions. On 01/09/2026 she received 25,000 shares of common stock as restricted stock awards under Lisata’s 2018 Equity Incentive Compensation Plan, vesting in four equal annual installments starting on the grant date. On the same date she was also granted stock options for 13,000 shares at an exercise price of $1.97 per share, with one-fourth vesting immediately and the rest in equal annual installments through 01/09/2036.
To cover tax liabilities from vesting restricted stock, multiple transactions coded “F” withheld a total of 11,332 common shares at $1.97 per share. Following these transactions, Buck directly beneficially owns 93,462 shares of common stock, which include 38,000 unvested restricted shares, as well as 13,000 stock options.
Lisata Therapeutics, Inc. director Steven M. Klosk received an equity award of 30,456 shares of common stock in the form of restricted stock units. The grant was made on January 9, 2026 under the company’s 2018 Equity Incentive Compensation Plan at a price of $0 per share, reflecting a compensatory award rather than a purchase.
The 30,456 restricted stock units will vest on January 9, 2027. After this grant, Klosk beneficially owns a total of 95,815 shares of common stock, which includes the 30,456 unvested restricted stock units reported in this filing, all held as direct ownership.
Lisata Therapeutics director Heidi Henson reported a new equity award. On January 9, 2026 she received 30,456 shares of common stock in the form of restricted stock units granted under Lisata’s 2018 Equity Incentive Compensation Plan at a grant price of $0 per share.
The restricted stock units are scheduled to vest on January 9, 2027, meaning the shares will become fully owned at that time if vesting conditions are met. After this grant, Henson beneficially owns 85,725 shares of Lisata common stock, which includes 30,456 unvested restricted stock units. The filing characterizes her ownership as direct.
Lisata Therapeutics director Cynthia Louise Flowers reported an equity grant from the company. On January 9, 2026, she was awarded 30,456 shares of common stock in the form of restricted stock units under Lisata’s 2018 Equity Incentive Compensation Plan at a grant price of $0 per share.
These 30,456 restricted stock units are scheduled to vest on January 9, 2027. After this grant, Flowers beneficially owns 95,446 shares of Lisata common stock, which includes the 30,456 unvested restricted stock units.
Lisata Therapeutics director Gregory B. Brown reported receiving 30,456 restricted stock units of common stock on January 9, 2026 under the company’s 2018 Equity Incentive Compensation Plan. These restricted stock units are scheduled to vest on January 9, 2027. Following this grant, he beneficially owns 95,659 shares of Lisata Therapeutics common stock, including 30,456 unvested restricted stock units.
Lisata Therapeutics director granted restricted stock units
Lisata Therapeutics, Inc. director Mohammad Azab reported an award of 30,456 shares of common stock on January 9, 2026. The filing states these are restricted stock units granted under the company’s 2018 Equity Incentive Compensation Plan and that they will vest on January 9, 2027. The units were recorded at a price of $0 per share, reflecting that this was an equity grant rather than an open-market purchase.
After this grant, Azab is reported to beneficially own 104,925 shares of common stock, which the disclosure notes includes 30,456 unvested restricted stock units. The ownership is reported as held directly.
Lisata Therapeutics (LSTA) filed its Q3 2025 10‑Q, reporting a quarterly net loss of $4.249 million as operating expenses declined to $4.414 million from $5.336 million a year ago. Revenue was $0 in the quarter and $70 thousand year‑to‑date.
Liquidity and balance sheet: Cash and cash equivalents were $18.998 million, with total assets of $21.759 million and stockholders’ equity of $17.373 million as of September 30, 2025. The company states it has sufficient cash to meet funding requirements over the next 12 months and expects to seek additional financing by the end of 2026.
Operations and expenses: R&D was $1.959 million and G&A was $2.455 million in Q3. Year‑to‑date, R&D totaled $6.815 million and G&A $8.385 million. The company continued Phase 2 studies of certepetide and delayed certain Phase 3 readiness activities to manage cash.
Capital actions: Lisata raised $600,663 in net proceeds via its ATM during the nine months ended September 30, 2025 and sold $10.7 million of New Jersey NOLs for net proceeds of $871 thousand, recording a $962 thousand deferred income tax benefit.
Lisata Therapeutics (LSTA) furnished an 8-K announcing a press release with financial results for the third quarter ended September 30, 2025, and a corporate presentation. The materials are included as Exhibits 99.1 and 99.2.
These disclosures were provided under Regulation FD and are being furnished, not filed, and therefore are not subject to Section 18 of the Exchange Act nor incorporated by reference except as expressly stated.